Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 sept. 2024 16h30 HE
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
18 sept. 2024 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 août 2024 16h30 HE
|
Tempest Therapeutics
BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
21 août 2024 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
15 août 2024 08h00 HE
|
Tempest Therapeutics
Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and scheduleOverall survival, the strongest result from the Phase 2 trial, will be the primary study...
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
08 août 2024 16h56 HE
|
Tempest Therapeutics
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across key subpopulationsa...
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
20 juin 2024 08h00 HE
|
Tempest Therapeutics
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis...
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
18 juin 2024 18h22 HE
|
Tempest Therapeutics
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 juin 2024 04h30 HE
|
Tempest Therapeutics
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...